Bayer faces glyphosate pressure as Bayer stock trades at EUR 44.58

Published on 10/07/2026 at 09:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer stock stood at EUR 44.58 versus EUR 44.25 on October 7, 2026. JPMorgan kept its Overweight rating and EUR 61.00 target on October 1, 2026.

Aquarellillustration der Skyline von Leverkusen mit Kühltürmen, Industrieschornsteinen und Hochhäusern am Rhein bei orangenem Abendhimmel, Beschriftung LEVERKUSEN — Aquarell-Panorama der Leverkusener Industrieskyline am Rhein bei Abendrot, Illustration mit AI erstellt.

Bayer (ISIN DE000BAY0017) was trading at EUR 44.58 at Lang & Schwarz on October 7, 2026, up 0.75 percent versus the prior close of EUR 44.25. As Boerse Express reported on October 6, 2026, renewed legal and regulatory uncertainty around glyphosate was weighing on the shares. Bayer stock therefore enters the next reporting phase with a modest daily gain but a still active litigation narrative.

Glyphosate risk meets Q3 expectations

EU member states have opposed indefinite approvals for plant-protection products, leaving glyphosate subject to time-limited authorization and regular reassessment, according to FinanzNachrichten on October 1, 2026. The same report linked the regulatory stance to higher uncertainty for Bayer's Crop Science business and noted pressure on the stock.

The next scheduled operating test is Bayer's third-quarter 2026 report on November 3, 2026, with publication set for 7:30 a.m. CET, according to Bayer. JPMorgan analyst Richard Vosser said early expectations for the quarter could be too high, while keeping the full-year estimates broadly unchanged.

Q2 growth offers an operational counterweight

Bayer's second-quarter 2026 group sales increased 2.2 percent on a currency and portfolio adjusted basis to EUR 10.872 billion. EBITDA before special items rose 1.9 percent to EUR 2.144 billion, according to Bayer. The comparison matters because it shows operating progress even as legal uncertainty continues to shape the valuation.

JPMorgan kept Bayer at Overweight and maintained its EUR 61.00 price target on October 1, 2026, according to finanzen.ch. The target lies 36.83 percent above the Lang & Schwarz price of EUR 44.58, but the analyst also pointed to timing effects in agriculture as a near-term constraint on third-quarter expectations.

Stock stays below its yearly high

Bayer's market capitalization was EUR 43.2 billion as of October 7, 2026, while its 52-week range was EUR 25.78 to EUR 53.92. The current price is 17.35 percent below that 52-week high, keeping the legal outlook and the November reporting date central to the stock's valuation.

Bayer was trading at EUR 44.58 at Lang & Schwarz on October 7, 2026 at 9:13 a.m. CEST, plus 0.75 percent versus the prior close of EUR 44.25. The further course of trading is shown by the continuously updated real-time quote of Bayer stock.